BioNTech 2026 AGM: Supervisory Board Expanded, $1B Buyback Announced, and Oncology Strategy Accelerated

BioNTech SE held its 2026 Annual General Meeting (AGM) on May 15, 2026, where shareholders approved all agenda items. Key outcomes include the expansion of the Supervisory Board from six to eight members to bolster oncology and commercialization expertise. Prof. Iris Löw-Friedrich and Susanne Schaffert were elected as new members, while Helmut Jeggle was re-elected and appointed Chairman. The company reaffirmed its 2026 financial guidance, targeting total revenues between €2.0 billion and €2.3 billion. BioNTech is shifting focus toward its late-stage oncology pipeline, specifically highlighting pumitamig (PD-L1xVEGF-A bispecific antibody) and various ADC candidates. The company expects more than 17 late-stage or pivotal trial readouts through 2030, with data from several lung and breast cancer trials anticipated in 2026. Additionally, BioNTech announced a share repurchase program of up to $1.0 billion over the next 12 months and a manufacturing footprint consolidation aimed at achieving €500 million in recurring annual savings by 2029. Q1 2026 results showed revenues of €118 million and a cash position of €16.8 billion.